|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
US20030026779A1
(en)
*
|
1999-10-15 |
2003-02-06 |
Liming Yu |
Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
|
|
US6114110A
(en)
*
|
1996-01-16 |
2000-09-05 |
University Of Michigan |
Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
|
|
US20050033033A1
(en)
*
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
|
US7569674B2
(en)
*
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
|
US20030103984A1
(en)
*
|
1998-05-04 |
2003-06-05 |
Heinz Kohler |
Fusion proteins of biologically active peptides and antibodies
|
|
US20040185039A1
(en)
*
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
US7026446B1
(en)
*
|
1997-12-24 |
2006-04-11 |
Diatech Pty Ltd. |
Bifunctional molecules
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
CN1318092C
(zh)
*
|
1998-04-15 |
2007-05-30 |
利思进药品公司 |
含有抗体-细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
|
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
|
SI1121382T1
(sl)
*
|
1998-10-16 |
2007-02-28 |
Biogen Idec Inc |
Fuzijski proteini interferona-beta in uporabe
|
|
AU766190B2
(en)
*
|
1998-10-16 |
2003-10-09 |
Biogen Idec Ma Inc. |
Interferon-beta fusion proteins and uses
|
|
DK1656952T3
(da)
|
1998-10-16 |
2014-01-20 |
Biogen Idec Inc |
Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
|
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6913749B2
(en)
*
|
1998-11-02 |
2005-07-05 |
Resistentia Pharmaceuticals Ab |
Immunogenic polypeptides for inducing anti-self IgE responses
|
|
KR20020018197A
(ko)
*
|
1999-05-19 |
2002-03-07 |
추후보정 |
Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
|
|
DE60034564T2
(de)
|
1999-07-07 |
2007-12-27 |
Zymogenetics, Inc., Seattle |
Menschlicher cytokinrezeptor
|
|
ATE407697T1
(de)
*
|
1999-07-13 |
2008-09-15 |
Bolder Biotechnology Inc |
Erythropoietin immunglobulin fusionsproteine
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
WO2001010912A1
(en)
*
|
1999-08-09 |
2001-02-15 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
WO2001053480A1
(en)
*
|
2000-01-24 |
2001-07-26 |
Sangamo Biosciences, Inc. |
Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
|
|
JP5179689B2
(ja)
*
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
CZ2003214A3
(cs)
*
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
US20020169290A1
(en)
*
|
2000-11-02 |
2002-11-14 |
Claus Bornaes |
New multimeric interferon beta polypeptides
|
|
WO2002036628A2
(en)
*
|
2000-11-02 |
2002-05-10 |
Maxygen Aps |
New multimeric interferon beta polypeptides
|
|
KR20030051897A
(ko)
*
|
2000-12-01 |
2003-06-25 |
다이버사 코포레이션 |
데할로게나제 활성을 가진 효소 및 이의 사용 방법
|
|
EP1355919B1
(de)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
|
US7141392B2
(en)
*
|
2001-01-09 |
2006-11-28 |
Queen Mary And Westfield College |
Latent fusion protein
|
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
|
FR2821625B1
(fr)
*
|
2001-03-01 |
2003-05-16 |
Genodyssee |
Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
|
|
CA2439636A1
(en)
|
2001-03-02 |
2002-09-12 |
Zymogenetics, Inc. |
Mouse cytokine receptor
|
|
US20030044406A1
(en)
*
|
2001-03-02 |
2003-03-06 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
|
|
DK1366067T3
(da)
*
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
CN1191271C
(zh)
*
|
2001-03-21 |
2005-03-02 |
中国科学院上海生物化学研究所 |
干扰素-胸腺肽融合蛋白及其制法
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
FR2823220B1
(fr)
*
|
2001-04-04 |
2003-12-12 |
Genodyssee |
Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
WO2002103321A2
(en)
*
|
2001-06-14 |
2002-12-27 |
Anadys Pharmaceuticals, Inc. |
Methods of screening for ligands of target molecules
|
|
ATE522603T1
(de)
*
|
2001-06-22 |
2011-09-15 |
Hoffmann La Roche |
Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
|
|
US6962982B2
(en)
*
|
2001-06-22 |
2005-11-08 |
Roche Diagnostics Corporation |
Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
|
|
US7094757B2
(en)
*
|
2001-06-22 |
2006-08-22 |
Roche Diagnostics Corporation |
Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
|
|
CA2452517A1
(en)
*
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
|
US20030104604A1
(en)
*
|
2001-08-03 |
2003-06-05 |
Weiping Yang |
Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
|
|
CN1405181A
(zh)
*
|
2001-08-10 |
2003-03-26 |
中国人民解放军军事医学科学院生物工程研究所 |
血清白蛋白与干扰素的融合蛋白
|
|
US6900292B2
(en)
*
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US6797493B2
(en)
|
2001-10-01 |
2004-09-28 |
Lee-Hwei K. Sun |
Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
|
|
EP1454138B1
(de)
*
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokine mit modulierter selektivität
|
|
PL374966A1
(en)
*
|
2002-02-21 |
2005-11-14 |
Wyeth |
Follistatin domain containing proteins
|
|
BR0307907A2
(pt)
*
|
2002-02-21 |
2011-07-05 |
Wyeth Corp |
gasp1: proteìna contendo domìnio de folistatina
|
|
AU2003210806A1
(en)
*
|
2002-03-05 |
2003-09-22 |
Eli Lilly And Company |
Heterologous g-csf fusion proteins
|
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
|
CA2492649A1
(en)
*
|
2002-07-17 |
2004-01-22 |
Biogen Idec Ma Inc. |
Therapies for renal failure using interferon-.beta.
|
|
JP4596916B2
(ja)
*
|
2002-09-05 |
2010-12-15 |
メディミューン,エルエルシー |
Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
|
|
AU2003267246A1
(en)
*
|
2002-09-16 |
2004-04-30 |
The Johns Hopkins University |
Metalloprotease activation of myostatin, and methods of modulating myostatin activity
|
|
DK1551876T3
(da)
|
2002-10-16 |
2011-06-14 |
Purdue Pharma Lp |
Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
|
|
US7261893B2
(en)
*
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
US20040223966A1
(en)
*
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
|
ATE471946T1
(de)
*
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
|
AU2004213565A1
(en)
*
|
2003-02-18 |
2004-09-02 |
Merck Patent Gmbh |
Fusion proteins of interferon alpha muteins with improved properties
|
|
WO2004091653A1
(en)
*
|
2003-04-17 |
2004-10-28 |
Ares Trading S.A. |
Interferon beta in severe acute respiratory syndrome (sars)
|
|
CN1535724B
(zh)
*
|
2003-04-23 |
2012-09-05 |
北京金迪克生物技术研究所 |
重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
SI1624891T2
(sl)
*
|
2003-05-06 |
2013-09-30 |
Biogen Idec Hemophilia Inc. |
Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
|
|
US7348004B2
(en)
*
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2004100882A2
(en)
*
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
|
US20070161087A1
(en)
*
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
|
WO2004108157A2
(en)
|
2003-06-02 |
2004-12-16 |
Wyeth |
Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
|
|
ES2371072T3
(es)
*
|
2003-06-12 |
2011-12-27 |
Eli Lilly And Company |
Proteínas de fusión análogas de glp-1.
|
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
|
BRPI0406605B8
(pt)
|
2003-11-13 |
2021-05-25 |
Hanmi Holdings Co Ltd |
conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
|
|
KR101163424B1
(ko)
|
2003-12-30 |
2012-07-13 |
메르크 파텐트 게엠베하 |
Il-7 융합 단백질
|
|
EP1699821B1
(de)
*
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
|
|
CA2553883C
(en)
*
|
2004-01-22 |
2013-04-02 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Anti-cancer antibodies with reduced complement fixation
|
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
MX2007000976A
(es)
*
|
2004-08-12 |
2007-04-10 |
Wyeth Corp |
Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
|
|
WO2006063055A2
(en)
*
|
2004-12-06 |
2006-06-15 |
Bolder Biotechnology, Inc. |
Enzyme conjugates for use as detoxifying agents
|
|
CN101072793B
(zh)
*
|
2004-12-09 |
2012-06-20 |
默克专利有限公司 |
具有降低的免疫原性的il-7变体
|
|
WO2006086396A2
(en)
|
2005-02-08 |
2006-08-17 |
Zymogenetics, Inc. |
Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
|
|
EP1864139A2
(de)
*
|
2005-03-23 |
2007-12-12 |
Wyeth |
Nachweis einer immunreaktion auf gdf-8-modulierende wirkstoffe
|
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
|
EP3683230A1
(de)
|
2005-05-12 |
2020-07-22 |
ZymoGenetics, Inc. |
Zusammensetzungen und verfahren zur modulation von immunsystemreaktionen
|
|
CN101184771A
(zh)
*
|
2005-05-26 |
2008-05-21 |
先灵公司 |
干扰素-IgG融合体
|
|
CA2619771C
(en)
*
|
2005-08-16 |
2012-05-22 |
Hanmi Pharmaceutical Co., Ltd. |
A method for the mass production of immunoglobulin fc region deleted initial methionine residues
|
|
EP1933860A2
(de)
|
2005-09-01 |
2008-06-25 |
Ares Trading S.A. |
Behandlung von optikusneuritis
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
AU2006332155B2
(en)
|
2005-12-30 |
2013-01-10 |
Cancer Research Technology Limited |
Anti-CD19 antibodies with reduced immunogenicity
|
|
SI1966238T1
(sl)
*
|
2005-12-30 |
2012-08-31 |
Merck Patent Gmbh |
Variante interlevkina-12P40 z izboljšano stabilnostjo
|
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
|
CA2650730A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
|
MX2008014971A
(es)
|
2006-05-24 |
2008-12-05 |
Serono Lab |
Regimen de cladribine para tratar esclerosis multiple.
|
|
KR20090039787A
(ko)
*
|
2006-07-18 |
2009-04-22 |
센토코 인코포레이티드 |
인간 glp-1 모방체, 조성물, 방법 및 용도
|
|
EP2484696B1
(de)
|
2006-08-28 |
2017-08-16 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistische hLIGHT-spezifische menschliche monoklonale Antikörper
|
|
EP2064335A4
(de)
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
|
|
US20090142362A1
(en)
*
|
2006-11-06 |
2009-06-04 |
Avant Immunotherapeutics, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
|
|
KR100888022B1
(ko)
|
2006-12-21 |
2009-03-09 |
재단법인 목암생명공학연구소 |
면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc
|
|
KR101540823B1
(ko)
|
2007-03-30 |
2015-07-30 |
메디뮨 엘엘씨 |
항체 제제
|
|
US7625555B2
(en)
|
2007-06-18 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human interferon-like proteins
|
|
US8067548B2
(en)
*
|
2007-07-26 |
2011-11-29 |
Novagen Holding Corporation |
Fusion proteins having mutated immunoglobulin hinge region
|
|
ES2536772T3
(es)
*
|
2007-09-21 |
2015-05-28 |
The Regents Of The University Of California |
El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
|
|
US7858759B2
(en)
|
2007-10-04 |
2010-12-28 |
Zymogenetics, Inc. |
Anti-zB7H6 antibody-drug conjugates
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
CN101918437B
(zh)
|
2007-11-21 |
2013-08-14 |
罗斯基勒大学 |
具有冰结合活性的多肽
|
|
US20110027337A1
(en)
*
|
2007-12-21 |
2011-02-03 |
Ifxa A/S |
Protease inhibitor
|
|
KR101720760B1
(ko)
*
|
2008-01-25 |
2017-03-28 |
오르후스 우니베르시테트 |
Igfbp-4에 대한 papp-a 활성의 선택적 엑소사이트 억제
|
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
|
EP2300501B1
(de)
|
2008-07-23 |
2014-08-20 |
Hanmi Science Co., Ltd. |
Polypeptidkomplex mit einem nicht-peptidyl-polymer mit drei funktionalen enden
|
|
EP2323679A4
(de)
|
2008-07-25 |
2012-08-22 |
Univ Colorado |
Clip-hemmer und verfahren zur modulierung der immunfunktion
|
|
AU2010238858A1
(en)
*
|
2009-04-22 |
2011-12-08 |
Merck Patent Gmbh |
Antibody fusion proteins with modified FcRn binding sites
|
|
EP2437767B1
(de)
|
2009-06-01 |
2015-07-08 |
MedImmune, LLC |
Moleküle mit verlängerter halbwertzeit und verwendungen dafür
|
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
|
EP2464661B1
(de)
|
2009-08-13 |
2018-01-17 |
The Johns Hopkins University |
Verfahren zur modulierung der immunfunktion mittles anti-b7-h7cr antikörper
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
PT2525787T
(pt)
*
|
2010-01-19 |
2017-12-18 |
Hanmi Science Co Ltd |
Formulações líquidas para conjugado de g-csf de longa ação
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
CN103119054B
(zh)
|
2010-03-26 |
2017-01-18 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
AR080993A1
(es)
|
2010-04-02 |
2012-05-30 |
Hanmi Holdings Co Ltd |
Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
|
|
US20110245469A1
(en)
*
|
2010-04-02 |
2011-10-06 |
Athena Discovery, Inc. |
Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives
|
|
JP5908888B2
(ja)
|
2010-04-16 |
2016-04-26 |
ヤンセン バイオテツク,インコーポレーテツド |
改変された植物のシステインプロテアーゼ及びその使用
|
|
EP2591000B1
(de)
|
2010-07-09 |
2017-05-17 |
Janssen Vaccines & Prevention B.V. |
Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
|
|
PT2591006T
(pt)
*
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
|
MX375112B
(es)
|
2010-07-09 |
2025-03-06 |
Biogen Hemophilia Inc |
Polipéptidos de factor ix y métodos para usarlos.
|
|
CN102585013B
(zh)
*
|
2011-01-07 |
2014-04-23 |
中国人民解放军军事医学科学院生物工程研究所 |
一种含有ω干扰素的融合蛋白及制备方法
|
|
US20120189633A1
(en)
|
2011-01-26 |
2012-07-26 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
CN102212139A
(zh)
*
|
2011-03-29 |
2011-10-12 |
中国人民解放军第二军医大学 |
森林脑炎病毒包膜E蛋白与人抗体Fc段融合蛋白及其用途
|
|
WO2013022328A1
(en)
*
|
2011-08-09 |
2013-02-14 |
Uab Profarma |
Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
|
|
FI2764565T3
(fi)
|
2011-10-05 |
2023-04-24 |
Oned Mat Inc |
Piin nanorakenteen aktiivimateriaaleja litiumioniakkuihin ja niihin liittyviä prosesseja, koostumuksia, komponentteja ja laitteita
|
|
CN104203982B
(zh)
|
2011-10-28 |
2018-08-31 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
|
US8883735B2
(en)
|
2011-11-04 |
2014-11-11 |
Novartis Ag |
Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
|
|
CN105001340A
(zh)
*
|
2012-01-19 |
2015-10-28 |
施怀哲维克有限公司 |
动物融合重组型干扰素
|
|
TWI492952B
(zh)
*
|
2012-01-20 |
2015-07-21 |
施懷哲維克有限公司 |
動物融合重組型干擾素
|
|
JP5855239B2
(ja)
|
2012-04-23 |
2016-02-09 |
株式会社Nrlファーマ |
ラクトフェリン融合タンパク質及びその製造方法
|
|
CN103044554B
(zh)
*
|
2012-05-14 |
2014-08-27 |
旭华(上海)生物研发中心有限公司 |
重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
|
|
WO2013177231A1
(en)
|
2012-05-21 |
2013-11-28 |
Massachusetts Institute Of Technology |
Translocation of non-natural chemical entities through anthrax protective antigen pore
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN104619722B
(zh)
*
|
2012-06-22 |
2022-10-04 |
达特茅斯大学理事会 |
新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
|
|
EP4063391A1
(de)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
|
SG11201502757QA
(en)
|
2012-10-09 |
2015-05-28 |
Igenica Biotherapeutics Inc |
Anti-c16orf54 antibodies and methods of use thereof
|
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
|
JP2016511747A
(ja)
|
2013-01-04 |
2016-04-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
ナノ粒子表面結合に基づく薬物の組織への送達
|
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
|
US9963515B2
(en)
|
2013-04-29 |
2018-05-08 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
|
EP3003390B1
(de)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54-antikörper und verwendungen davon
|
|
WO2014202089A2
(en)
|
2013-06-18 |
2014-12-24 |
Roskilde Universitet |
Variants of anti-freeze polypeptides
|
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
|
CN105764526B
(zh)
|
2013-08-26 |
2020-12-15 |
生物技术研发公司 |
编码抗唾液酸化路易斯a抗原的人抗体的核酸
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
US10273301B2
(en)
|
2013-12-24 |
2019-04-30 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
RS60593B1
(sr)
|
2014-01-24 |
2020-08-31 |
Ngm Biopharmaceuticals Inc |
Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
|
WO2015161832A1
(zh)
*
|
2014-04-25 |
2015-10-29 |
辅仁药业集团有限公司 |
长效重组人干扰素α2b-Fc融合蛋白
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
ES2913205T3
(es)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Proteínas biológicas activas condicionalmente
|
|
JP6832709B2
(ja)
|
2014-05-16 |
2021-02-24 |
メディミューン,エルエルシー |
新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
|
|
US9856324B2
(en)
|
2014-06-04 |
2018-01-02 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
|
|
US10513699B2
(en)
|
2014-09-03 |
2019-12-24 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
PE20170908A1
(es)
|
2014-10-29 |
2017-07-12 |
Teva Pharmaceuticals Australia Pty Ltd |
VARIANTES DE INTERFERON a2b
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
MX2017007136A
(es)
|
2014-12-05 |
2017-12-04 |
Immunext Inc |
Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
|
|
KR102693806B1
(ko)
|
2014-12-11 |
2024-08-09 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
|
SG11201705988UA
(en)
|
2015-02-24 |
2017-08-30 |
Bioatla Llc |
Conditionally active biological proteins
|
|
PL3265123T3
(pl)
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Przeciwciała, zastosowania i sposoby
|
|
EA201792442A1
(ru)
|
2015-05-06 |
2018-06-29 |
Янссен Байотек, Инк. |
Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
|
|
EP3722314A1
(de)
|
2015-06-24 |
2020-10-14 |
Janssen Pharmaceutica NV |
Anti-vista-antikörper und -fragmente
|
|
MX2018002183A
(es)
|
2015-08-27 |
2018-05-28 |
Harvard College |
Composiciones y metodos para tratamiento del dolor.
|
|
TW201718629A
(zh)
*
|
2015-09-25 |
2017-06-01 |
韓美藥品股份有限公司 |
包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物
|
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
|
CA3003399A1
(en)
|
2015-11-02 |
2017-05-11 |
Bioatla, Llc |
Conditionally active polypeptides
|
|
US10899836B2
(en)
|
2016-02-12 |
2021-01-26 |
Janssen Pharmaceutica Nv |
Method of identifying anti-VISTA antibodies
|
|
CN117986363A
(zh)
|
2016-03-31 |
2024-05-07 |
恩格姆生物制药公司 |
结合蛋白及其使用方法
|
|
PE20190115A1
(es)
|
2016-04-15 |
2019-01-16 |
Immunext Inc |
Anticuerpos vista antihumanos y su uso
|
|
EP3515944A4
(de)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Verfahren zur behandlung von immunerkrankungen unter verwendung von pd-1 bindenden proteinen
|
|
EP3515943A4
(de)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
|
|
EP3533870A4
(de)
|
2016-10-28 |
2020-04-08 |
NRL Pharma, Inc. |
Lactoferrin/albumin-fusionsprotein und herstellungsverfahren dafür
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
|
AR113906A1
(es)
|
2017-11-24 |
2020-06-24 |
Merck Patent Ges Mit Beschraenkter Haftung |
Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
|
|
KR20250024129A
(ko)
|
2018-07-20 |
2025-02-18 |
피에르 파브르 메디카먼트 |
Vista의 수용체
|
|
SG11202102851XA
(en)
|
2018-09-27 |
2021-04-29 |
Celgene Corp |
SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
|
|
US12653899B2
(en)
*
|
2019-07-26 |
2026-06-16 |
Massachusetts Institute Of Technology |
Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues
|
|
EP4176893A4
(de)
*
|
2020-07-01 |
2024-10-23 |
Institute of Biophysics Chinese Academy of Sciences |
Konstruktion und anwendung einer fusionsproteinimpfstoffplattform
|
|
JP7846667B2
(ja)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
Cd20結合分子及びその使用
|
|
CA3186065A1
(en)
|
2020-07-16 |
2022-01-20 |
Xiaohu FAN |
Cd19 binding molecules and uses thereof
|
|
TW202212354A
(zh)
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
|
IL301246A
(en)
|
2020-09-10 |
2023-05-01 |
Merck Patent Gmbh |
Treatment regimen with cladribine
|
|
US20250199010A1
(en)
|
2020-12-31 |
2025-06-19 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
|
EP4047016A1
(de)
|
2021-02-19 |
2022-08-24 |
Université de Strasbourg |
Anti-tenascin-c(tnc)-antikörper (nanobodies) mit einer einzigen domäne und deren verwendung
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
|
IL328264A
(en)
|
2023-11-14 |
2026-07-01 |
Janssen Pharmaceuticals Inc |
Anti-Respiratory Syncytial Virus Antibodies and Their Uses
|